4.7 Review

Role of endothelin in the cardiovascular system

期刊

PHARMACOLOGICAL RESEARCH
卷 63, 期 6, 页码 463-472

出版社

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2011.01.014

关键词

Endothelin; Endothelium; Cardiovascular diseases; Endothelin receptor antagonists

资金

  1. Ministerio de Ciencia e Innovacion [SAF2006-02410, SAF2009-09085, SAF2009-07520, CSD-2007-0020]
  2. Comunidad Autonoma de Madrid (CARDIOVREP Consortium)
  3. Sociedad Espanola de Nefrologia
  4. Fundacion Medica Mutua Madrilena
  5. Fundacion Renal Inigo Alvarez de Toledo (FRIAT)
  6. Fundacion Genoma Espana
  7. Ministerio de Ciencia e Innovacion

向作者/读者索取更多资源

The endothelin (ET) system consists of three peptide ligands (ET-1, ET-2 and ET-3) and two G-protein-coupled receptors, ETA and ETB. In the cardiovascular system, ETs, particularly ET-1, are expressed in smooth muscle cells, cardiomyocytes, fibroblasts, and notably in vascular endothelial cells. Intense research over the last 10 years has changed the original view of ET-1 as mainly a vasoconstrictor regulating blood pressure, into a biological factor regulating processes such as vascular remodeling, angiogenesis or extracellular matrix synthesis. The advent of specific (and type-selective) ET receptor antagonists has greatly fostered our knowledge of the biological function of ET-1, and has offered a potential therapeutic approach for numerous diseases including hypertension, atherosclerosis or fibrosis. In this article, we review the regulation of the expression of vascular ET-1, as well as the contribution of ET-1 to endothelial, smooth muscle and fibroblast cell function, with particular interest in the role of ET-1 in the development of cardiovascular diseases. (C) 2011 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据